leuprolide acetate
information and resources from the National Cancer Institute
leuprolide acetate
The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.
|
|
|
|
news articles
Children With GERD Can Go Undiagnosed for Months Mar 22, 2006
EndoNurse, Pharmaceutical Company Limited, of Osaka, Japan. TAP markets Prevacid and Lupron Depot® (leuprolide acetate for depot suspension).
Dendreon Names Christopher Lockett Head of Government Affairs Mar 23, 2006
Yahoo! News (press release) ...federal programs, including Medicare and Medicaid, as well as legislative issues on TAP's two leading products, Lupron Depot® (leuprolide acetate for depot ...
Children with Pediatric Gastroesophageal Reflux Disease (GERD) Can ... Mar 22, 2006
PharmaLive.com (press release), Limited, of Osaka, Japan. TAP markets Prevacid and Lupron Depot(R) (leuprolide acetate for depot suspension). For more information ...
Voyager Pharmaceutical Corporation Adds Six New Board Members Mar 3, 2006
Carolina Newswire (press release), Voyager's most advanced product candidate is Memryte, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer, that ...
TAP Licenses Prevacid Intellectual Property Rights to Novartis for ... 21 Dec 2005
PharmaLive.com (press release), ...of Osaka, Japan. TAP markets Prevacid® (lansoprazole) and Lupron Depot® (leuprolide acetate for depot suspension). For more information ...
Voyager Pharma pulls IPO, cites market conditions Dec 13, 2005
Triangle Tech Journal (press release), ...candidate is Memryte, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer that it is developing for the treatment ...
Voyager Pharmaceutical Corporation Withdraws Initial Public ... Dec 14, 2005
dBusinessNews Triangle (press release), Voyager's most advanced product candidate is Memryte, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer that it ...
Docs Assess Three Therapy Approaches for Poor IVF Responders Nov 30, 2005
Fertility Neighborhood, The so-called stop protocol at the clinic involved the use of Lupron (leuprolide acetate), a GnRH agonist given during the mid-luteal phase of the patient's ...
|
|
